Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial
Introduction: Management of persistently non-adherent youth living with HIV (YLHIV) with virologic failure (VF) on combination antiretroviral therapy (cART) remains challenging. One strategy has been using 3TC/FTC monotherapy (3TC/FTC), which in the presence of the M184V resistance mutation, does no...
Saved in:
Main Authors: | Allison L. Agwu, Meredith G. Warshaw, Elizabeth J. McFarland, George K. Siberry, Ann J. Melvin, Andrew A. Wiznia, Lee Fairlie, Sandra Boyd, Paul Harding, Hans M.L. Spiegel, Elaine J. Abrams, Vincent J. Carey, Murli Purswani, Linda Aurpibul, Virat Sirisanthana, Chintana Khamrong, Joan Wilson, Margaret Donnelly, John Swetnam, Erica Stankievich, Silvina A. Ivalo, Irene Foradori, Ivete Martins Gomes, Jose Henrique Pilotto, Cintia Lopes Da Silva, Marinella Della Negra, Yu Ching Lian, Denise Peluso Pacola, Thuy C. Anderson, Todd C. Noletto |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85020697190&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56516 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial
by: Agwu A., et al.
Published: (2017) -
Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial
by: Allison L. Agwu, et al.
Published: (2018) -
Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe
by: L. Stranix-Chibanda, et al.
Published: (2020) -
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial
by: Theodore D. Ruel, et al.
Published: (2022) -
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living with HIV: Week 24 Results from IMPAACT 2014
by: Melvin A.J.
Published: (2023)